The 'Bio International Convention (Bio USA),' which had been suspended for in-person events due to the COVID-19 pandemic, se celebrará in person por primera vez in three years este año. With el mercado global de bio inversión mercado currently contratoed, attention is focused on whether Korean bio empresas can achieve resultados in tecnología exports, atracción de inversiones, and contrato signings.
Según industria sources on the 7th, more than 3,200 empresas worldwide are set to participate in the '2022 Bio USA,' which se celebrará in San Diego, USA for three days starting from the 13th (local time). Companies headquartered in Korea are esperado to number 255 (by corporate name). Including overseas-headquartered empresas such as NeoImmuneTech, K-bio empresas are the second largest participant group after the United States.
The Korea Biotecnología Industry Organization will operate the Korea Pavilion with KOTRA, introducing 12 empresas including Standigm, Kangstem Biotech (217730), LSK Global Pharma Services, and RudaCure. A representative from the association dijo, "Este año's Bio USA will showcase the current state of desarrollo de nuevos fármacos pipelines as well as new technologies from digital healthcare empresas that developed during the COVID-19 period to the mercado global."
Source: https://www.sedaily.com/NewsView/2675KPF54D
